410 related articles for article (PubMed ID: 28515094)
41. Twist1 Inactivation in Dmp1-Expressing Cells Increases Bone Mass but Does Not Affect the Anabolic Response to Sclerostin Neutralization.
Lewis KJ; Choi RB; Pemberton EZ; Bullock WA; Firulli AB; Robling AG
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31505764
[TBL] [Abstract][Full Text] [Related]
42. Sclerostin is overexpressed by plasma cells from multiple myeloma patients.
Brunetti G; Oranger A; Mori G; Specchia G; Rinaldi E; Curci P; Zallone A; Rizzi R; Grano M; Colucci S
Ann N Y Acad Sci; 2011 Nov; 1237():19-23. PubMed ID: 22082361
[TBL] [Abstract][Full Text] [Related]
43. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats.
Ominsky MS; Brown DL; Van G; Cordover D; Pacheco E; Frazier E; Cherepow L; Higgins-Garn M; Aguirre JI; Wronski TJ; Stolina M; Zhou L; Pyrah I; Boyce RW
Bone; 2015 Dec; 81():380-391. PubMed ID: 26261096
[TBL] [Abstract][Full Text] [Related]
44. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
[TBL] [Abstract][Full Text] [Related]
45. Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta.
Little DG; Peacock L; Mikulec K; Kneissel M; Kramer I; Cheng TL; Schindeler A; Munns C
Bone; 2017 Aug; 101():96-103. PubMed ID: 28461254
[TBL] [Abstract][Full Text] [Related]
46. Mechanisms of bone destruction in multiple myeloma.
Terpos E; Christoulas D; Gavriatopoulou M; Dimopoulos MA
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28940410
[TBL] [Abstract][Full Text] [Related]
47. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis.
Eddleston A; Marenzana M; Moore AR; Stephens P; Muzylak M; Marshall D; Robinson MK
J Bone Miner Res; 2009 Oct; 24(10):1662-71. PubMed ID: 19419292
[TBL] [Abstract][Full Text] [Related]
48. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2.
Kogawa M; Wijenayaka AR; Ormsby RT; Thomas GP; Anderson PH; Bonewald LF; Findlay DM; Atkins GJ
J Bone Miner Res; 2013 Dec; 28(12):2436-48. PubMed ID: 23737439
[TBL] [Abstract][Full Text] [Related]
49. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.
Terpos E; Christoulas D; Katodritou E; Bratengeier C; Gkotzamanidou M; Michalis E; Delimpasi S; Pouli A; Meletis J; Kastritis E; Zervas K; Dimopoulos MA
Int J Cancer; 2012 Sep; 131(6):1466-71. PubMed ID: 22052418
[TBL] [Abstract][Full Text] [Related]
50. Sclerostin antibody prevents particle-induced implant loosening by stimulating bone formation and inhibiting bone resorption in a rat model.
Liu S; Virdi AS; Sena K; Sumner DR
Arthritis Rheum; 2012 Dec; 64(12):4012-20. PubMed ID: 23192793
[TBL] [Abstract][Full Text] [Related]
51. Sclerostin expression in bone tumours and tumour-like lesions.
Inagaki Y; Hookway ES; Kashima TG; Munemoto M; Tanaka Y; Hassan AB; Oppermann U; Athanasou NA
Histopathology; 2016 Sep; 69(3):470-8. PubMed ID: 26896083
[TBL] [Abstract][Full Text] [Related]
52. Hyaluronan hydrogels delivering BMP-6 for local targeting of malignant plasma cells and osteogenic differentiation of mesenchymal stromal cells.
Grab AL; Seckinger A; Horn P; Hose D; Cavalcanti-Adam EA
Acta Biomater; 2019 Sep; 96():258-270. PubMed ID: 31302300
[TBL] [Abstract][Full Text] [Related]
53. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Croucher PI; Shipman CM; Van Camp B; Vanderkerken K
Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581
[TBL] [Abstract][Full Text] [Related]
54. [Bone and Nutrition. Sclerostin and bone metabolism].
Tatsumi S; Nagamoto K; Ogata M; Miyamoto K
Clin Calcium; 2015 Jul; 25(7):1043-7. PubMed ID: 26119318
[TBL] [Abstract][Full Text] [Related]
55. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.
Poole KE; van Bezooijen RL; Loveridge N; Hamersma H; Papapoulos SE; Löwik CW; Reeve J
FASEB J; 2005 Nov; 19(13):1842-4. PubMed ID: 16123173
[TBL] [Abstract][Full Text] [Related]
56. Disparate bone anabolic cues activate bone formation by regulating the rapid lysosomal degradation of sclerostin protein.
Gould NR; Williams KM; Joca HC; Torre OM; Lyons JS; Leser JM; Srikanth MP; Hughes M; Khairallah RJ; Feldman RA; Ward CW; Stains JP
Elife; 2021 Mar; 10():. PubMed ID: 33779549
[TBL] [Abstract][Full Text] [Related]
57. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.
Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ
Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248
[TBL] [Abstract][Full Text] [Related]
58. Sclerostin antibody prevented progressive bone loss in combined ovariectomized and concurrent functional disuse.
Zhang D; Hu M; Chu T; Lin L; Wang J; Li X; Ke HZ; Qin YX
Bone; 2016 Jun; 87():161-8. PubMed ID: 26868528
[TBL] [Abstract][Full Text] [Related]
59. Sclerostin: from bench to bedside.
Tanaka S; Matsumoto T
J Bone Miner Metab; 2021 May; 39(3):332-340. PubMed ID: 33206222
[TBL] [Abstract][Full Text] [Related]
60. Systemic sclerostin antibody treatment increases osseointegration and biomechanical competence of zoledronic-acid-coated dental implants in a rat osteoporosis model.
Korn P; Kramer I; Schlottig F; Tödtman N; Eckelt U; Bürki A; Ferguson SJ; Kautz A; Schnabelrauch M; Range U; Kneissel M; Stadlinger B
Eur Cell Mater; 2019 May; 37():333-346. PubMed ID: 31112281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
